Opko Executive Investment Will Buy 12 Months; 2008 Losses Decline | GenomeWeb

Opko Health expects to be able to fund its operations into early 2010 after an investment group controlled by the company's chairman and CEO agreed to by $20 million worth of the ophthalmic drug and device shop's stock, according to a US Securities and Exchange Commission filing published this week.

Also in the filing, Opko disclosed its financial results for 2008 and provided an update on a legal dispute in which it has been charged with illegally interfering with the business of a rival.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.